Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen's Neuroscience Strategy Includes De-Risking The Pipeline

Executive Summary

Biogen is laser-focused on leading neuroscience, but management also talked about ways to balance the high-risk nature of competing in the challenging therapeutic area.

Advertisement

Related Content

Takeda Catches Rising Tide Of Antisense Neuroscience R&D
Biopharma Quarterly Deal-Making Statistics, Q2 2017
Commercial Capsules: Q2 Reporters, Mitsubishi Buy, Celltrion IPO, Renflexis Launch, Keytruda Fail, Ironwood and Vertex Trial Results
Commercial Capsules: Q2 Reporters, Mitsubishi Buy, Celltrion IPO, Renflexis Launch, Keytruda Fail, Ironwood and Vertex Trial Results
2Q Pharma Results Preview: Lilly, Biogen, Amgen, GSK And Gilead
Biogen Builds Out Neuroscience Niche With Ischemic Stroke Drug
Biogen Staying "Laser-Focused" On Neuroscience
Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal
Neuroscience Reaches A New Inflection Point, Big Biotechs Say

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel